Calman MacLennan

Calman MacLennan is Professor of Vaccine Immunology at the University of Birmingham and a Jenner Investigator and Group Leader at the Jenner Institute, University of Oxford. He is Director of BactiVac, the Bacterial Vaccines Network, and holds a clinical role as Consultant Immunologist at Oxford University Hospitals NHS Foundation Trust. He also serves as Senior Program Officer for Bacterial Vaccines at the Bill & Melinda Gates Foundation. His work bridges academia, industry, and global health policy.

MacLennan's research focuses on understanding immune protection against bacterial pathogens of global significance, particularly those causing enteric diseases and antimicrobial resistance. His work leverages advanced platforms such as glycoconjugate and outer membrane vesicle (OMV) vaccines. Key areas include Salmonella, Shigella, and Neisseria gonorrhoeae, with an emphasis on vaccine development for low-resource settings.

The most recent publications highlight a strong trend in vaccine development, correlates of protection, and global burden of bacterial diseases. His team is advancing multivalent and combination vaccines, particularly using the MAPS platform, and exploring regulatory and implementation pathways for new vaccines in endemic regions. There is a consistent focus on translating immunological insights into practical public health solutions.

Scientific awards and honors include:

• Fellow of the Higher Education Academy (FHEA)
• Fellow of the Royal College of Physicians (FRCP)
• Fellow of the Royal College of Pathologists (FRCPath)

MacLennan leads major grant-funded initiatives, including BactiVac, which fosters international collaboration in bacterial vaccine development. He advises global health bodies such as WHO and works closely with the Gates Foundation. His work involves extensive mentorship and collaboration, though specific student names are not listed in the provided text.

He leads the Gonococcal Vaccine Project at the Jenner Institute, which is developing a native OMV-based vaccine against Neisseria gonorrhoeae. This project is part of a broader effort within the Jenner Institute and BactiVac network to combat antimicrobial-resistant pathogens through innovative vaccinology.